Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13541878 | 0.88 | TSHR (0.33) | TDP1TSHRAKR1B1KDM1AMAOB | |
| SCHEMBL7598821 | 0.74 | TDP1 (0.45) | TDP1TSHRHTR2AAKR1B1KDM1A | |
| SCHEMBL5687667 | 0.72 | KDM1A (0.50) | TDP1TSHRHTR2AKDM1AMAOB | |
| SCHEMBL6077160 | 0.70 | AKR1B1 (0.46) | TDP1TSHRHTR2AAKR1B1KDM1A | |
| SCHEMBL31347965 | 0.70 | TSHR (0.45) | TDP1TSHRHTR2AAKR1B1KDM1A | |
| SCHEMBL8222603 | 0.70 | TSHR (0.45) | TDP1TSHRHTR2AAKR1B1KDM1A | |
| SCHEMBL6337745 | 0.67 | HDAC9 (0.49) | TDP1TSHRHTR2AAKR1B1KDM1A | |
| SCHEMBL7040158 | 0.67 | KDM1A (0.46) | TDP1TSHRHTR2AKDM1AMAOB | |
| SCHEMBL30364417 | 0.67 | TSHR (0.49) | TDP1TSHRAKR1B1NPC1MAPK13 | |
| SCHEMBL15518954 | 0.66 | KDM1A (0.44) | TDP1TSHRHTR2AKDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008748-A1 | COMPOUNDS WITH BIGUANIDYL RADICAL AND USES THEREOF | INST CURIE (FR) | 2026-01-08 | — | — | US | disclosed |
| US-12415781-B2 | Compounds with biguanidyl radical and uses thereof | INSTITUT CURIE (FR) | 2025-09-16 | — | — | US | disclosed |
| US-7642283-B2 | modulating the activity of the mitochrondrial permeability transition pore complex comprising exposing the complex to a compound such as 6-bromo-3-methylene-chroman-4-one | HOFFMANN-LA ROCHE INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642283-B2 | modulating the activity of the mitochrondrial permeability transition pore complex comprising exposing the complex to a compound such as 6-bromo-3-methylene-chroman-4-one | HOFFMANN-LA ROCHE INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642283-B2 | modulating the activity of the mitochrondrial permeability transition pore complex comprising exposing the complex to a compound such as 6-bromo-3-methylene-chroman-4-one | HOFFMANN-LA ROCHE INC. (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1468995-B1 | MPTP affinity labels | HOFFMANN LA ROCHE (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-20060252822-A1 | Mitochrondrial permeability transition pore affinity labels and modulators | CESURA ANDREA | 2006-11-09 | — | — | US | disclosed |
| US-7101917-B2 | Mitochrondrial permeability transition pore affinity labels and modulators | HOFFMANN-LA ROCHE INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040220257-A1 | Mitochrondrial permeability transition pore affinity labels and modulators | HOFFMANN-LA ROCHE INC. | 2004-11-04 | — | — | US | disclosed |
| EP-1468995-A1 | MPTP affinity labels | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220257-A1 | Mitochrondrial permeability transition pore affinity labels and modulators | MCU, ATP5PB, MFN2 | TDP1 1749/4885TSHR 4156/4885HTR2A 2650/4885 |
| US-12415781-B2 | Compounds with biguanidyl radical and uses thereof | OGG1, MGMT, DPYD | TDP1 565/4885TSHR 3096/4885HTR2A 3366/4885 |
| US-20060252822-A1 | Mitochrondrial permeability transition pore affinity labels and modulators | MCU, ATP5PB, MFN2 | TDP1 1749/4885TSHR 4156/4885HTR2A 2650/4885 |
| US-20260008748-A1 | COMPOUNDS WITH BIGUANIDYL RADICAL AND USES THEREOF | CBR3, ROS1, CBR1 | TDP1 2568/4885TSHR 2199/4885HTR2A 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.